| abstract |
Compositions for the diagnosis and treatment of bladder, lung, ovarian, and renal cancer, derived from or based on a normally prostate-specific, androgen-regulated cell membrane-bound secreted serine protease called 20P1F12 / TMPRSS2 Disclose things. A full-length cDNA (also referred to herein as 20P1F12-GTC1) containing the entire coding sequence of the 20P1F12 / TMPRSS2 gene is provided (FIG. 1). The components provided include antibodies that bind to the 20P1F12 / TMPRSS2 protein, including antibodies labeled with a detectable marker or toxin, and polypeptide fragments thereof, or therapeutic compositions. The present invention also provides a diagnostic and prognostic test for examining a biological sample for evidence of uncontrolled cell proliferation by comparing the status of 20P1F12 / TMPRSS2 to that of a corresponding normal sample. A method wherein the change in the status of 20P1F12 / TMPRSS2 in the biological sample is related to uncontrolled cell growth. In addition, the present invention provides various therapeutic compositions and strategies for treating bladder, lung, ovarian, and kidney cancer, particularly 20P1F12 / TMPRSS2 antibody therapy and compositions, cancer vaccines, and small molecules. Including therapy. |